Potassium Citrate ER Tablets (10 mEq)

Potassium citrate is a potassium salt that delivers both potassium and citrate. The extended‐release (ER) tablet slowly releases these ions in the gut. Citrate is metabolized to bicarbonate, producing an alkali load that raises blood and urine pH. In practice, potassium citrate helps neutralize acid in the body and urine and supplies potassium (to correct or prevent hypokalemia). Its net effect is to make the urine less acidic, which reduces formation of acid‐related kidney stones. Potassium citrate ER is available as 5, 10 or 15 mEq tablets (10 mEq ≈ 1080 mg salt). It is a prescription drug (brand name Urocit‐K and generics) typically taken by mouth with meals and a full glass of water to minimize gastrointestinal irritation.

Uses (Indications)

Potassium citrate extended‐release is used primarily to prevent and treat certain metabolic and urinary conditions:

• Renal tubular acidosis (RTA) – Particularly type I (distal) RTA, often associated with calcium kidney stones. By providing alkali (citrate/bicarbonate), it corrects the acidosis and helps dissolve or prevent stone formation.
• Hypocitraturic calcium nephrolithiasis – In patients who form calcium-oxalate stones due to low urinary citrate (“hypocitraturia”), potassium citrate raises urinary citrate and pH, reducing stone formation.
• Uric acid stones (and gout) – Potassium citrate alkalinizes urine so guanine-type uric acid is more soluble. It is indicated for uric acid nephrolithiasis (with or without calcium stones). In gout or hyperuricemia, alkalinizing the urine can help reduce uric acid crystallization.
• Prevent recurrence of kidney stones – More generally, patients with recurrent calcium or uric acid stones due to acidic urine or low citrate often use potassium citrate for prevention.

Other uses include treating systemic acidosis (e.g. from chronic diarrhea) and sometimes adjunctive therapy in metabolic conditions (always under physician guidance). Some sources note use to help prevent gout attacks (by alkalinizing blood/urine). (It is not effective against infections or systemic fungal disease; its role is metabolic.)

Mechanism of Action

Potassium citrate works as a systemic alkalinizer. The citrate ion is absorbed and converted to bicarbonate, providing an alkaline load. This raises blood bicarbonate and urine pH. Higher urinary pH and citrate have several effects:

• Increased urinary citrate: Citrate normally complexes with calcium. Potassium citrate therapy increases urinary citrate by altering renal handling of citrate. The extra citrate binds calcium in the urine, lowering “ionized” calcium and inhibiting crystallization of calcium salts.
• Higher urine pH: By making urine more alkaline, potassium citrate reduces the supersaturation of uric acid (which is more soluble as urate at higher pH) and also helps dissolve some calcium salts. In effect, the urine becomes less conducive to calcium oxalate, calcium phosphate, and uric acid stone formation.
• Potassium repletion: Each tablet also delivers potassium. This prevents or corrects hypokalemia that often accompanies RTA or diuretic use (though RTA type I usually causes calcinosis, not hypokalemia; type II or other causes may).

In summary, potassium citrate provides alkali and citrate to restore normal urinary citrate (>320 mg/day) and a target pH of ~6.0–7.0. This makes urine less acidic and less likely to precipitate stone-forming crystals. (As an example of dosing effect, 60 mEq/day of potassium citrate raises urinary citrate by ~400 mg/day.

Dosage and Administration

• Typical dosing: Adults often require total daily doses in the range of 30–60 mEq per day, divided with meals. For example, severe hypocitraturia (urinary citrate <150 mg/day) may be treated with 60 mEq/day (such as 20 mEq three times daily or 30 mEq twice daily), according to official guidelines. Milder cases may use 30 mEq/day (e.g. 10 mEq three times daily or 15 mEq twice daily). The 10 mEq ER tablets make it easy to combine multiple tablets per dose. (Because this is an ER form, high single doses are possible, but splitting doses improves tolerability; e.g. 20 mEq = two 10-mEq tablets.)
• Administration: Swallow the tablets whole with a full glass of water; do not chew, crush, or suck on them. Take with or shortly after meals or bedtime snacks to reduce stomach upset. Doses should be evenly spaced (e.g. morning and evening, or thrice daily) to maintain steady urinary alkalinization. Do not take more often than prescribed.
• Special instructions: Encourage a low-sodium diet and high fluid intake (aim for ≥2 liters urine output/day) while on therapy . High fluids and low salt optimize stone prevention. The goal is to gradually restore urinary citrate above ~320 mg/day and achieve a urine pH in the 6–7 range.
• Dose adjustments: Renal impairment: Do not use potassium citrate in significant kidney failure (GFR <0.7 mL/kg·min)) because the kidneys cannot excrete extra potassium. No specific dose reduction is given other than avoidance. In mild to moderate renal insufficiency, use with caution and monitor potassium closely. Pediatrics: Safety and dosing in children have not been established – pediatric formulations (syrup or powder) are used instead of adult ER tablets.

Always follow the prescribing information or physician’s orders. Do not self-titrate. Therapy is often long-term. Treatment is stopped if goals are reached or if contraindications arise.

Side Effects and Safety

Gastrointestinal: The most common side effects are GI-related. Because the tablets are alkaline salts, they can irritate the gastrointestinal lining. Patients may experience nausea, vomiting, diarrhea or abdominal discomfort. Starting with smaller doses or taking with food/liquid usually alleviates these. Rarely, the tablets can ulcerate the esophagus or stomach if not swallowed properly. Symptoms like difficulty swallowing, throat pain, heartburn or GI bleeds have been reported. To minimize risk, always take with plenty of water, remain upright, and do not crush the tablet.

Hyperkalemia: Because this drug provides potassium, it can cause high blood potassium (hyperkalemia) if potassium excretion is impaired. Warning symptoms include muscle weakness, tingling or irregular heartbeat. Hyperkalemia has on occasion led to cardiac arrest. Potassium citrate should never be used in patients with preexisting hyperkalemia or conditions limiting potassium excretion (e.g. chronic renal failure, uncontrolled diabetes, Addison’s disease, severe dehydration). If hyperkalemia occurs, stop the drug. Patients should have periodic lab tests (potassium, bicarbonate, creatinine) to monitor for rising levels.

Allergic and other reactions: True allergic reactions are rare but possible. Report any rash, itching, hives or swelling. Other uncommon effects include dizziness or weakness. High doses of potassium citrate have occasionally been linked to lead to GI bleeding or perforation if a tablety fragment lodges in the bowel, so persistent abdominal pain or vomiting should prompt medical evaluation. If any severe signs occur (e.g. dark stools, bloody vomit, severe abdominal pain), discontinue medication and seek help.

Pregnancy and lactation: Use only if clearly needed. Animal studies are lacking; human data are insufficient. Pregnancy category is not clearly established. Because sodium bicarbonate and potassium citrate sources can affect acid/base balance, this should only be used under medical supervision in pregnancy. Potassium is excreted in breast milk in amounts roughly proportional to blood levels – nursing mothers should use caution and consult a doctor.

Overall, the ER tablets are usually well tolerated if used correctly. Staying hydrated and following dosing instructions greatly reduce side effects. Chronic high doses (much above 60–90 mEq/day) increase risk of GI upset and hyperkalemia..

Contraindications and Precautions

Contraindications: Do not use potassium citrate if you have any existing hyperkalemia or conditions that predispose to it (advanced kidney failure, untreated Addison’s disease, severe ascites, acute dehydration, crush injuries, etc.). Also avoid in renal insufficiency (markedly reduced GFR). Active urinary tract infection is a contraindication because infection can acidify urine and promote struvite stones. Avoid if you have delayed GI transit, e.g. strictures, obstruction or severe gastroparesis or active peptic ulcer disease, as ER tablets can get stuck and irritate.

Interactions: Combining potassium citrate with other agents that raise potassium can cause dangerous hyperkalemia. Avoid concomitant use of potassium‐sparing diuretics (e.g. spironolactone, eplerenone, amiloride, triamterene). Also use caution (and monitor labs) if on ACE inhibitors, ARBs or NSAIDs, since these can increase serum potassium. Do not use with other potassium supplements, potassium-containing salt substitutes or potassium mesylate/phosphate without close supervision – additive effects can push K too high. Certain drugs that slow gut motility (anticholinergics, some antihistamines) can exacerbate GI irritation by keeping the tablet in the esophagus/stomach longer. If taking any multiple medications, inform your doctor as others (e.g. digoxin, beta-blockers, some anti-arrhythmics) may interact indirectly via potassium shifts.

Monitoring: Patients on long-term therapy should have periodic blood tests (electrolytes including K, bicarbonate, creatinine) and possibly EKGs. If any dose increases are made (e.g. to reach stone prevention goals), repeat labs to avoid asymptomatic hyperkalemia. If kidney function worsens or potassium rises, the drug must be stopped. Also monitor blood count if used very long-term (rare cases of blood dyscrasias have been reported).

Dietary precautions: The prescribing info advises a low-sodium diet to enhance citrate retention. Patients should avoid high-potassium foods or salt substitutes while taking this drug, unless their doctor has directed otherwise. Drinking plenty of fluids (water) is essential to flush the kidneys.

Summary

Potassium citrate ER (10 mEq tablets) is an alkalinizing potassium supplement used mainly for kidney stone prevention and RTA management. By raising blood/urine pH and urinary citrate, it reduces calcium and uric acid stone formation. Typical adult regimens involve 10–20 mEq per dose, 2–3 times daily with meals. Side effects are primarily GI upset (nausea, diarrhea); serious toxicity stems from hyperkalemia if used improperly. To use it safely, take the ER tablets whole with water, follow dosing instructions, and have periodic lab monitoring. It should not be used in those with high baseline potassium or severe renal insufficiency.